MetLife Investment Management’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.03M | Buy |
14,746
+222
| +2% | +$30.5K | 0.01% | 981 |
|
|
2025
Q1 | $2.62M | Sell |
14,524
-473
| -3% | -$85.3K | 0.01% | 913 |
|
|
2024
Q4 | $2.35M | Buy |
14,997
+680
| +5% | +$107K | 0.01% | 959 |
|
|
2024
Q3 | $2.61M | Hold |
14,317
| – | – | 0.01% | 887 |
|
|
2024
Q2 | $2.63M | Buy |
14,317
+3,213
| +29% | +$590K | 0.02% | 850 |
|
|
2024
Q1 | $1.98M | Sell |
11,104
-267
| -2% | -$47.5K | 0.01% | 956 |
|
|
2023
Q4 | $1.41M | Hold |
11,371
| – | – | 0.01% | 1126 |
|
|
2023
Q3 | $1.32M | Hold |
11,371
| – | – | 0.01% | 1093 |
|
|
2023
Q2 | $1.33M | Buy |
11,371
+190
| +2% | +$22.3K | 0.01% | 1114 |
|
|
2023
Q1 | $895K | Hold |
11,181
| – | – | 0.01% | 1268 |
|
|
2022
Q4 | $886K | Hold |
11,181
| – | – | 0.01% | 1280 |
|
|
2022
Q3 | $779K | Buy |
11,181
+915
| +9% | +$63.8K | 0.01% | 1318 |
|
|
2022
Q2 | $674K | Hold |
10,266
| – | – | 0.01% | 1455 |
|
|
2022
Q1 | $683K | Buy |
10,266
+3,618
| +54% | +$241K | ﹤0.01% | 1584 |
|
|
2021
Q4 | $465K | Hold |
6,648
| – | – | ﹤0.01% | 1546 |
|
|
2021
Q3 | $347K | Hold |
6,648
| – | – | ﹤0.01% | 1741 |
|
|
2021
Q2 | $452K | Buy |
6,648
+1,015
| +18% | +$69K | ﹤0.01% | 1628 |
|
|
2021
Q1 | $434K | Hold |
5,633
| – | – | ﹤0.01% | 1610 |
|
|
2020
Q4 | $338K | Hold |
5,633
| – | – | ﹤0.01% | 1693 |
|
|
2020
Q3 | $243K | Hold |
5,633
| – | – | ﹤0.01% | 1744 |
|
|
2020
Q2 | $233K | Buy |
5,633
+1,124
| +25% | +$46.6K | ﹤0.01% | 1809 |
|
|
2020
Q1 | $195K | Hold |
4,509
| – | – | ﹤0.01% | 1710 |
|
|
2019
Q4 | $250K | Hold |
4,509
| – | – | ﹤0.01% | 1852 |
|
|
2019
Q3 | $157K | Hold |
4,509
| – | – | ﹤0.01% | 2076 |
|
|
2019
Q2 | $182K | Buy |
+4,509
| New | +$182K | ﹤0.01% | 2084 |
|